J&J tries and fails to get biosims case tossed

Aug 13, 2018

A federal judge has dismissed a bid by Johnson & Johnson to toss a lawsuit from Pfizer claiming that its biosimilar was edged out of the market by unfair marketing practices.

According to the suit, J&J made deals with pharmacy benefit managers and insurers to maintain a dominance in the market for rheumatoid arthritis and its blockbuster medication, Remicade. Pfizer alleges that the practices kept lower-cost alternatives, including its biosimilar, Inflectra, from gaining any ground.

But J&J has countered that the competition did not provide enough value to patients. The company also argued that Pfizer did not have sufficient evidence for a lawsuit — but a federal judge in Philadelphia disagreed.

Now that the case will be allowed to proceed, it will be closely watched by the industry and could set a precedent for how other lawsuits regarding biosimilars are decided. 

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments